

1. Name and Address of Reporting Person *			2. Issuer Name and Ticker or Trading Symbol			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)		
Silva Francisco			BioRestorative Therapies, Inc. [ BRTX ]			<input checked="" type="checkbox"/> Director 10% Owner		
(Last) (First) (Middle)			3. Date of Earliest Transaction (Month/Day/Year)			<input checked="" type="checkbox"/> Officer (give title below) Other (specify below)		
40 MARCUS DRIVE			11/04/2021			VP of Research and Development		
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)			6. Individual or Joint/Group Filing (Check Applicable Line)		
MELVILLE NY 11747						<input checked="" type="checkbox"/> Form filed by One Reporting Person		
(City) (State) (Zip)						Form filed by More than One Reporting Person		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock								148,848 <sup>(1)(2)</sup>	D	
Common Stock								3 <sup>(2)</sup>	I	IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option	\$3,000							11/16/2011	11/15/2021	Common Stock	1 <sup>(2)</sup>		1 <sup>(2)</sup>	D	
Stock Option	\$3,000							(3)	02/09/2022	Common Stock	1 <sup>(2)</sup>		1 <sup>(2)</sup>	D	
Stock Option	\$3,000							(4)(3)	05/02/2022	Common Stock	1 <sup>(2)</sup>		1 <sup>(2)</sup>	D	
Stock Option	\$3,000							(3)	12/07/2022	Common Stock	1 <sup>(2)</sup>		1 <sup>(2)</sup>	D	
Stock Option	\$3,000							(3)	10/04/2023	Common Stock	1 <sup>(2)</sup>		1 <sup>(2)</sup>	D	
Stock Option	\$3,000							(3)	02/18/2024	Common Stock	3 <sup>(2)</sup>		3 <sup>(2)</sup>	D	
Stock Option	\$3,000							03/12/2014	03/11/2024	Common Stock	1 <sup>(2)</sup>		1 <sup>(2)</sup>	D	
Stock Option	\$3,000							04/14/2014	05/02/2022	Common Stock	1 <sup>(2)</sup>		1 <sup>(2)</sup>	D	
Stock Option	\$3,000							(3)	10/23/2024	Common Stock	9 <sup>(2)</sup>		9 <sup>(2)</sup>	D	
Stock Option	\$3,000							(3)	09/04/2025	Common Stock	6 <sup>(2)</sup>		6 <sup>(2)</sup>	D	
Stock Option	\$3,000							(3)	06/10/2026	Common Stock	15 <sup>(2)</sup>		15 <sup>(2)</sup>	D	
Stock Option	\$3,000							(3)	07/12/2027	Common Stock	20 <sup>(2)</sup>		20 <sup>(2)</sup>	D	
Stock Option	\$3,000							(3)	10/29/2028	Common Stock	25 <sup>(2)</sup>		25 <sup>(2)</sup>	D	
Stock Option	\$47.6	11/04/2021		D			293,479 <sup>(2)</sup>	(5)	03/18/2031	Common Stock	293,794 <sup>(2)</sup>	\$0 <sup>(7)</sup>	0	D	
Stock Option	\$13.5	11/04/2021		A		293,479		(6)	03/18/2031	Common Stock	293,479	\$0 <sup>(7)</sup>	293,479	D	
Stock Option	\$13.5	11/04/2021		A		42,059		(8)	11/04/2031	Common Stock	42,059	\$0	42,059	D	

Explanation of Responses:

1. Includes 146,740 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 48,914 shares on March 18, 2022 and 48,913 shares on each of March 18, 2023 and March 18, 2024.

2. Reflects a 1-for-4,000 reverse split effected by the issuer on October 27, 2021.

3. The option is currently exercisable.

4. The option is exercisable subject to the satisfaction of certain conditions.

5. The option vests to the extent of 146,740 shares on March 18, 2021, 73,370 shares on March 18, 2022 and 73,369 shares on March 18, 2023.

6. The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 and the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.

7. The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option with an adjusted exercise price and vesting dates.

8. The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.

/s/ Francisco Silva

11/08/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**